Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849078 | 0.81 | ELANE (0.65) | MGLLPOLBHPGDHSD17B10MEN1 | |
| SCHEMBL9471172 | 0.78 | FAAH (0.40) | MGLLFAAHPOLBL3MBTL1HPGD | |
| SCHEMBL11443380 | 0.77 | APAF1 (0.61) | MGLLPOLBNPSR1ESR1ESR2 | |
| SCHEMBL10799063 | 0.77 | F2 (0.43) | MGLLFAAHPOLBHSD17B10MEN1 | |
| SCHEMBL10934452 | 0.77 | ALDH1A1 (0.56) | MGLLNPSR1HSD17B10ESR2MEN1 | |
| SCHEMBL19708009 | 0.77 | ELANE (0.65) | MGLLFAAHPOLBHPGDNPSR1 | |
| SCHEMBL19707275 | 0.76 | FAAH (0.60) | MGLLFAAHPOLBL3MBTL1HPGD | |
| 3,4-Dimethylphenylmaleimide SCHEMBL5074358 | 0.76 | PARP1 (0.53) | MGLLL3MBTL1HPGDNPSR1HSD17B10 | |
| SCHEMBL3619832 | 0.76 | KMT2A (0.64) | MGLLFAAHESR1ESR2MEN1 | |
| SCHEMBL30390220 | 0.76 | KMT2A (0.64) | MGLLFAAHESR1ESR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365984-B | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2024-10-15 | — | — | CN | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| CN-113365984-A | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-09-07 | — | — | CN | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
| CN-112243440-A | Hexahydroxypyrrolo [3,4-c ] pyrrole derivatives useful as LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-01-19 | — | — | CN | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
| CN-105038069-B | Gate insulation layer for electronic device | 默克专利股份有限公司 | 2017-10-17 | — | — | CN | disclosed |
| EP-2676978-A1 | Interlayer for electronic devices | Merck Patent GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2676979-A1 | Gate insulator layer for electronic devices | Merck Patent GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| CN-103261250-A | Gate insulator layer for electronic devices | MERCK PATENT GMBH | 2013-08-21 | — | — | CN | disclosed |
| EP-2611842-A1 | INTERLAYER FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611841-A1 | GATE INSULATOR LAYER FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| CN-103097420-A | Interlayer for electronic devices | MERCK PATENT GMBH | 2013-05-08 | — | — | CN | disclosed |
| US-20120056249-A1 | INTERLAYER FOR ELECTRONIC DEVICES | PROMERUS LLC (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2012028278-A1 | INTERLAYER FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028279-A1 | GATE INSULATOR LAYER FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20120056183-A1 | GATE INSULATOR LAYER FOR ORGANIC ELECTRONIC DEVICES | PROMERUS LLC (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | MGLL 44/4885FAAH 394/4885POLB 2119/4885 |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | MGLL 666/4885FAAH 1057/4885POLB 2518/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | MGLL 666/4885FAAH 1057/4885POLB 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.